Morgan Stanley analyst Hamza Fodderwala maintains ForgeRock (NYSE:FORG) with a Equal-Weight and lowers the price target from $27 to $22.
CytomX Therapeutics Q1 EPS $(0.37) Misses $(0.36) Estimate, Sales $17.10M Miss $20.66M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.36) by 2.78 percent. This is a 42.31 percent decrease over losses of $(0.26) per share
